In the realm of metabolic targeting, iRGD-exosome-mediated delivery of siRNA of carnitine palmitoyl transferase 1A (CPT1A), a key enzyme in fatty acid oxidation (FAO), was shown to effectively reverse oxaliplatin resistance and inhibit tumor growth in colon cancer by disrupting the FAO metabolic pathways, with a high safety profile in vivo [220]. This evidence concerns the gene CPT1A and malignant colon neoplasm.